Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Genomics is transforming the future of modern medicine and treatment modalities across specialties
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The supply of these goods is set to commence within the first quarter of FY26
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
